The first real-world picture of how quickly the oral semaglutide tablet entered US prescribing is out, and the answer is: fast. A peer-reviewed research letter published in October analyzed deidentified records from a national electronic health network covering more than 300 million patients and found that weekly initiation of oral semaglutide rose from nearly zero to a peak of about 4.56 starts per 10,000 eligible adults roughly ten weeks after the tablet's December 2025 approval for weight management — briefly overtaking the injectable version of the same molecule.
What Happened
The retrospective study drew on electronic health record data spanning more than 2,000 hospitals and roughly 47,000 clinics. Of nearly 48 million US adults who qualified for obesity medication — a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition such as hypertension or obstructive sleep apnea — about 148,800 initiated oral semaglutide during the study window, compared with roughly 227,000 who started injectable semaglutide and 355,500 who started tirzepatide.
Most oral initiators, 87.6%, received the tablet approved for weight management; the rest received the diabetes formulation of the same molecule. Tirzepatide nonetheless retained the highest weekly initiation rate throughout the entire period.
Who Is Affected
- Adults eligible for obesity medication, who now have a tablet option whose uptake briefly outpaced the flagship injection
- Primary care and family medicine clinicians, who wrote roughly half of all initiating prescriptions for each of the three drugs
- Gray-market observers, since every approved oral product historically pulls demand away from unregulated research-product sellers
Timeline
- December 2025 — US regulators approve the once-daily oral semaglutide tablet for chronic weight management, the first oral GLP-1 option for that indication
- March 2026 — Weekly initiation peaks at 4.56 per 10,000 eligible adults, briefly exceeding injectable semaglutide
- October 2026 — The research letter is published with the full real-world uptake analysis
What This Means for Researchers
Two signals stand out. First, 53% of oral semaglutide initiators had not used any GLP-1 therapy in the prior twelve months — the tablet is expanding the treated population rather than just shuffling existing patients between products. Second, uptake still trailed tirzepatide, which the study authors suggest may reflect tirzepatide's stronger reputation for weight-loss efficacy.
For the research community, the arrival of approved oral options matters because pill-form demand previously flowed heavily toward unregulated sellers marketing oral GLP-1 compounds for research use. As approved tablets normalize, that gray-market pressure should ease. The authors are careful about limits, though: prescription orders do not prove dispensing, and a descriptive study cannot adjust for confounding.
How to Verify Your Peptides
Whether a compound arrived through a pharmacy or the gray market, independent analysis is the only trustworthy check:
- Start with how independent testing works
- Compare HPLC and LC-MS verification methods
- Learn to read identity, purity, and fill-weight certificates
Safe Alternatives
- Explore our research compound library
- See our verified vendor listings
Sources
- A peer-reviewed research letter analyzing US electronic health record data, published October 2026
- Regulatory announcements on the December 2025 approval of oral semaglutide for weight management
- Industry reports on oral GLP-1 prescribing trends (2026)